RPRX Form 4: EVP acquires 6,168 shares via Rule 16b-3 award
Royalty Pharma plc (RPRX) reported an insider transaction on a Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) reported an insider transaction on a Form 4. The EVP, Investments & CLO acquired 6,168 Class A Ordinary Shares on 11/05/2025 at $0, an exempt acquisition under Rule 16b-3 tied to the settlement of Equity Performance Awards.
Following the transaction, the reporting person lists beneficial ownership across multiple indirect entities, including GWL 2023 G HoldCo LLC, GWL 2013 NG, LLC, an IRA, GWL 2014 G, LLC, GWL 2020 G, LLC, GWL 2021 G, LLC, and by spouse, as well as 3,000 shares held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Ordinary Shares | 6,168 | $0.00 | $0.00 |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
| Holding | Class A Ordinary Shares | -- | -- | -- |
Footnotes (1)
- F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
